Zacks: Analysts Expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Will Post Earnings of -$0.59 Per Share
Wall Street brokerages expect that Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) will announce earnings of ($0.59) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Momenta Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.81). Momenta Pharmaceuticals reported earnings per share of ($0.07) during the same quarter last year, which indicates a negative year-over-year growth rate of 742.9%. The company is scheduled to issue its next quarterly earnings report on Friday, February 28th.
According to Zacks, analysts expect that Momenta Pharmaceuticals will report full-year earnings of ($2.58) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($2.10). For the next financial year, analysts expect that the business will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.51) to ($1.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Momenta Pharmaceuticals.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.09). Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The firm had revenue of $6.40 million for the quarter, compared to analyst estimates of $5.24 million. During the same period in the previous year, the business posted ($0.65) earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 57.0% on a year-over-year basis.
Shares of MNTA stock opened at $16.61 on Friday. Momenta Pharmaceuticals has a 12 month low of $9.51 and a 12 month high of $17.56. The firm has a market capitalization of $1.66 billion, a P/E ratio of -8.18 and a beta of 2.07. The company’s fifty day moving average price is $15.50 and its two-hundred day moving average price is $13.04.
In other news, SVP Santiago Arroyo sold 6,318 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $13.83, for a total value of $87,377.94. Following the completion of the sale, the senior vice president now owns 33,272 shares of the company’s stock, valued at approximately $460,151.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Craig A. Wheeler sold 66,666 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $17.00, for a total transaction of $1,133,322.00. Following the completion of the sale, the chief executive officer now owns 79,343 shares in the company, valued at approximately $1,348,831. The disclosure for this sale can be found here. Insiders have sold a total of 143,928 shares of company stock worth $2,305,814 over the last quarter. 3.40% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the stock. Metropolitan Life Insurance Co NY lifted its holdings in Momenta Pharmaceuticals by 1.9% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 32,021 shares of the biotechnology company’s stock worth $415,000 after buying an additional 596 shares during the last quarter. Arizona State Retirement System raised its position in shares of Momenta Pharmaceuticals by 0.7% during the 2nd quarter. Arizona State Retirement System now owns 152,967 shares of the biotechnology company’s stock valued at $1,904,000 after acquiring an additional 1,003 shares in the last quarter. United Services Automobile Association raised its position in shares of Momenta Pharmaceuticals by 0.9% during the 2nd quarter. United Services Automobile Association now owns 218,633 shares of the biotechnology company’s stock valued at $2,722,000 after acquiring an additional 1,890 shares in the last quarter. CWM Advisors LLC raised its position in shares of Momenta Pharmaceuticals by 17.2% during the 2nd quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 2,020 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in Momenta Pharmaceuticals by 5.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 39,254 shares of the biotechnology company’s stock worth $489,000 after purchasing an additional 2,074 shares during the last quarter. Institutional investors and hedge funds own 97.04% of the company’s stock.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
See Also: Why is insider trading harmful?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.